Description: Absci Corporation, an AI-powered synthetic biology company, offers biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Home Page: www.absci.com
ABSI Technical Analysis
18105 SE Mill Plain Boulevard
Vancouver,
WA
98683
United States
Phone:
360 949 1041
Officers
| Name | Title |
|---|---|
| Mr. Sean McClain | Founder, CEO, Pres & Director |
| Dr. Sarah Korman J.D., Ph.D. | Chief Legal Officer & Corp. Sec. |
| Mr. Gregory T. Schiffman CPA, CPA, MBA | Chief Financial Officer |
| Todd Bedrick CPA | Sr. VP & Chief Accounting Officer |
| Mr. Jack Gold | Chief Marketing Officer |
| Melissa Patterson Ph.D. | Chief of Staff |
| Ms. Denise Dettore | Chief People Officer |
| Dr. Andreas Busch Ph.D. | Chief Innovation Officer |
| Jonathan Eads M.S. | Sr. VP of Informatics |
| Thomas Wrona J.D., Ph.D. | Sr. VP of Intellectual Property |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.8264 |
| Price-to-Sales TTM: | 42.7421 |
| IPO Date: | 2021-07-22 |
| Fiscal Year End: | December |
| Full Time Employees: | 211 |